about
Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptionsPerspectives for immunotherapy: which applications might achieve an HIV functional cure?Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in ChinaLessons from acute HIV infection.Genetic vaccination against experimental infection with myotropic parasite strains of Trypanosoma cruzi.Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trialInitiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationArming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection.HIV DNA Vaccine: Stepwise Improvements Make a Difference.Brief Report: Role of Thymic Reconstitution in the Outcome of AIDS-Related PMLThe therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study.The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?Human Immunodeficiency Virus (HIV).Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquineTargeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions.Ageing with HIV: a multidisciplinary review.Toward a cure for HIV--Seeking effective therapeutic vaccine strategies.Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand.Kill: boosting HIV-specific immune responses.Therapy of HIV Infection: Current Approaches and Prospects.A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.[Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health].HIV reservoirs as obstacles and opportunities for an HIV cure.Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4⁺ T-cell-dependent natural killer cell effector responses in chronically infected rhesus macaques.Embracing the complexity of HIV immunology.Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Use of 'eradication' in HIV cure-related research: a public health debate.
P2860
Q26777442-AC21701C-9251-41A8-B700-1E03C4CF29EEQ28078726-C658348A-4E88-42B4-A689-566189D41AD2Q28544731-41868172-25F1-4D6B-9E14-E411EC47F100Q30490195-D7906DE1-BA26-486F-9AED-F94621E049C3Q33902471-77F808B8-74C6-46C9-939B-1D2001E605B5Q34513477-C5426A44-0F5E-4923-ADF3-473CF61FF5C0Q34682171-58ED0A21-83B1-4A7A-80CE-5B4C2A5A2075Q35752258-CB63B306-9AFD-4B34-A03B-0910CD78122AQ35826742-C717E009-CCC8-4B09-A8A5-38C01CD1A83BQ36220004-378C12FD-61AD-4A26-B860-9745B673D3C7Q36322493-70657132-A5B6-47C6-9782-1C0181F84D6AQ36580911-CB94F1D0-C142-4B2F-961D-DB60A5C51DEAQ36827134-0FCD92F6-7A34-4C89-8CC3-AEAA3D8FA19EQ37045832-437198F6-45D1-4C03-863F-F29DC3575456Q37587740-E85DDA75-C8D4-4A5C-93A5-3C4697C713EFQ37643349-DC5D53D1-6D7E-447A-8143-DC9B4A6925CDQ38246141-69820470-50A1-4FDF-873D-08FBCA4E9558Q38490362-A0EF698D-0524-491C-A6D0-6605FD0A426EQ38626469-235D747C-6B8C-4167-A102-6ACF6BE16038Q38660440-26620A15-E501-4202-8415-42322A0740B4Q38800533-74488CE9-8C8F-4251-B8A4-2BCA55415799Q39066550-DA80C64A-EE91-438C-9956-374E13BE2828Q40919787-1F931177-916D-480D-9DD1-231FC6631EB0Q40942917-0C86D2D4-8389-42FB-8645-44B69B868DEFQ41216521-11E51BC7-528F-4CDE-95A8-7AD8398AB38BQ41519074-BDB9009A-7AC7-4A6E-9DBE-0C841956507CQ46770038-51BF49CC-B998-424E-A922-598E95366E2AQ47170671-00C0EA82-CC51-4601-80C5-0A65955C887CQ47548487-64D733B5-54EF-48FC-B71C-0D5C2CFCEA4CQ50032569-158BCAEE-2F96-4C88-BEE7-E42B0C85E6EA
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Immune interventions in HIV infection.
@ast
Immune interventions in HIV infection.
@en
Immune interventions in HIV infection.
@nl
type
label
Immune interventions in HIV infection.
@ast
Immune interventions in HIV infection.
@en
Immune interventions in HIV infection.
@nl
prefLabel
Immune interventions in HIV infection.
@ast
Immune interventions in HIV infection.
@en
Immune interventions in HIV infection.
@nl
P2860
P356
P1476
Immune interventions in HIV infection.
@en
P2093
Guislaine Carcelain
P2860
P304
P356
10.1111/IMR.12083
P577
2013-07-01T00:00:00Z